Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.

doi:10.1200/PO.22.00258

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.

JCO precision oncology - 1 Jan 2023

Pujade-Lauraine Eric, Brown Jessica, Barnicle Alan, Wessen Jonathan, Lao-Sirieix Pierre, Criscione Steven W, du Bois Andreas, Lorusso Domenica, Romero Ignacio, Petru Edgar, Yoshida Hiroyuki, Vergote Ignace, Colombo Nicoletta, Hietanen Sakari, Provansal Magali, Schmalfeldt Barbara, Pignata Sandro, Martín Lorente Cristina, Berton Dominique, Runnebaum Ingo B, Ray-Coquard Isabelle

Abstract excerpt

PURPOSE: The PAOLA-1/ENGOT-ov25 trial of maintenance olaparib plus bevacizumab for newly diagnosed advanced high-grade ovarian cancer demonstrated a significant progression-free survival (PFS) benefit over placebo plus bevacizumab, particularly in patients with homologous recombination deficiency (HRD)-positive tumors. We explored whether mutations in non-BRCA1 or BRCA2 homologous recombination repair (non-BRCA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bevacizumab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomic Instability

Share to Mutation

Share to Ovarian cancer diagnosis and treatment

Share to Ovarian Neoplasms

Share to PARP inhibition in cancer therapy

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Recombinational DNA Repair

Source

Open in PubMed Open full text

Identifiers

PMID: 36716415
DOI: 10.1200/PO.22.00258
PMCID: PMC9928987

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.PMID 36716415Read ↗

Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancerSemantic proximity Read ↗

Mutational Signature-Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High-Grade Ovarian Cancer.Semantic proximity Read ↗

Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic AberrationsSemantic proximity Read ↗

Ovarian carcinoma patients with a tumor<i>BRCA</i>-like genomic copy number aberration profile benefit from maintenance olaparib/bevacizumab therapy in the PAOLA-1 randomized controlled trialSemantic proximity Read ↗

Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian CarcinomaSemantic proximity Read ↗

Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib.Semantic proximity Read ↗

Normalized LST is an efficient biomarker for homologous recombination deficiency and Olaparib response in ovarian carcinomaSemantic proximity Read ↗

Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.Semantic proximity Read ↗

Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian CancerSemantic proximity Read ↗

Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trialSemantic proximity Read ↗

Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.Semantic proximity Read ↗

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.